Digna Biotech S.L

FDA grants cardiotrophin-1 Orphan Drug status for acute liver failure treatment to Digna Biotech

Digna Biotech receives FDA approval for cardiotrophin-1 as an acute liver failure treatment. The medicine is expected to work by acting as a messenger to damaged liver cells, helping them recover and restoring function. Cardiotrophin-1 has been shown to stimulate hepatic regeneration and protect hepatocytes during acute hepatic damage.

SourceDigna Biotech S.L·DateSep 22, 2011

Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome

Researchers discovered that cardiotrophin 1 accelerates fat elimination from adipose tissue, increases muscle fat burning, and improves glucose uptake in cells. Treatment of obese mice with cardiotrophin 1 also reduces food intake and corrects obesity and diabetes.

SourceDigna Biotech S.L·JournalCell Metabolism·DateSep 13, 2011